Lunit Oncology

🤝 A great opportunity to use Lunit SCOPE IO for SITC member’s research!

📢 Please join us at #IO360summit for the presentation by Lunit’s Global VP of Translational Medicine, Dr. Siraj Ali, who will discuss how AI-powered digital pathology, including deep learning analysis of H&E and IHC images, can significantly speed up biomarker development across all clinical stages and how innovative AI applications can be leveraged to support various drug classes. Hope to see you there! #ConquerCancerThroughAI Contact us: https://lnkd.in/g2qjX989

How can #AI help with the challenges for IHC-based biomarker development? 🔬 Each IHC slide holds much more information on a subcellular level than a slide-level summary score such TPS or H-score, however, it is labor intensive for human pathologists to calculate the expression on a subcellular level on a continuous scale over thousands of cells. Also, standardization has been a longstanding challenge due to inter-observer/laboratory variabilities, and interpretation subjectivities. 💡 How can Lunit #SCOPE uIHC (universal IHC) help with these challenges?  - SCOPE uIHC can quantify #subcellular localization of the target expression (membrane, cytoplasm, nucleus) - The target staining intensity on each cell can be quantified on a #continuous scale of 0-100% across many different tumor types and targets.  - Spatial analysis on the target expression and their relationship to other cells, including tumor cell vs immune cell vs normal cell identification - Based on the features above, SCOPE uIHC can enable flexible hypothesis checking and biomarker formation, even from #singleplex IHC 💊 Lunit SCOPE uIHC can accelerate biomarker development in multiple ways: - As an exploratory analysis tool for target protein expression quantification (e.g., for ADCs or bispecifics), assessing tumor cell specificity and membrane specificity of a given target. - Discovery of innovative biomarker scoring strategies and evaluation of cut-off parameters. - Detailed analysis results could help find new biomarkers by enabling precise intensity assessment, subcellular localization and ratio biomarkers, tumor cell proximity biomarkers, and more Research Use Only. Lunit SCOPE uIHC is not approved for use in diagnostic procedures. Learn more about how Lunit SCOPE #uIHC: https://lnkd.in/gca8q_P4

Amazing opportunity for #SITC members to apply for the #Lunit research program. The application period runs through April 30, 2025. Learn more: sitcancer.org/lunit

How can #AI help with the challenges for genotype testing?  Even though genotype testing including EGFR has been routinely implemented for many years, the test rate for #NSCLC is between ~60% to 80%. This means that ~20% to 40% of NSCLC patients may not be getting the best therapy or clinical trial for their cancer. Current challenges for molecular testing: Long #TAT (turn around time) for the test: Up to 3 to 4 weeks for an NGS test result Lack of tumor #tissue: Around 15% of NSCLC patients may not have sufficient tissue sample for an EGFR test How can Lunit #SCOPE Genotype Predictor help with these problems? SCOPE GP can predict genotype based on the H&E slide with a short TAT. Research Use Only. Lunit SCOPE GP is not approved for use in diagnostic procedures. Learn more about how Lunit SCOPE GP can accelerate clinical trials: https://lnkd.in/gXEegTKk

We're excited to share our collaboration with SITC to offer free access to Lunit #SCOPE IO for SITC members. The application period runs until the end of Apr. Please see below for more information. Learn more: sitcancer.org/lunit

The flexible architecture of our HALO AP platform allows for seamless third-party integrations, including AI-driven tools like Lunit SCOPE PD-L1 from Lunit Oncology. These integrations empower pathologists with enhanced diagnostic capabilities and streamlined workflows, all within a single platform. Explore how HALO AP is transforming pathology practices with comprehensive, integrated solutions tailored for today’s diagnostic and clinical research demands in our recent application note: https://lnkd.in/gV2aSqFH #DigitalPathology #AImicroscopy #TissueAnalysis #IndicaLabs #LungCancer #LunitSCOPE #HALOap 

We’re excited to announce our new publication on LunitSCOPE #HER2 and #IO. This new publication in collaboration with #NCCHE (National Cancer Center Hospital East in Japan) highlights enhanced HER2 assessment accuracy and improved prediction of treatment response and outcomes using Lunit SCOPE #HER2. Also, using Lunit SCOPE #IO, the study performed detailed TME profiling, including lymphocyte, macrophage, and fibroblast densities. Among AI-H3(HER2 IHC 3+)-high patients, those with low stromal TME density (TME-low) achieved the most favorable outcomes. “This study underscores the potential of AI technology to redefine how we evaluate biomarkers and predict treatment responses,” said Dr. Takayuki Yoshino of the National Cancer Center Hospital East, principal investigator of the research. “The ability to more precisely stratify patients will lead to more personalized treatment options, improving outcomes for patients with HER2-positive metastatic colorectal cancer.” Click the link below to see the full article: #lunit #HER2 #IO https://lnkd.in/g7jgH4Vn

2025 will be an exciting year for #Lunit Oncology! 2024 has been a transformative journey for Lunit, filled with exciting partnerships, collaborations with academia, and innovations that are at the forefront of what AI can do to help more cancer patients. Here’s how #Lunit will continue to push the boundaries of technology evolution: 🧑🏻💻 Advancing Foundation Models • Our foundation model has demonstrated versatile and efficient performance already.  • In 2025, we look forward to scaling up and advancing our foundation models through data, model architecture, and multi-modalities. 💡 Product Innovation • We released Lunit SCOPE #GP (Genotype Predictor) to predict risk for genomic aberrations based on a H&E slide • Upgraded Lunit SCOPE #uIHC to provide subcellular stain localization, continuous intensity scoring, and cell type identification. • Lunit SCOPE #IO was upgraded for better tissue segmentation including necrosis and TLS, and cell segmentation for fibroblasts, endothelial cells, macrophages, etc.  • In 2025, we look forward to introducing new product features as well as new product lines to drive even more biopharma innovation. 🤝 Expanding Partnerships • The partnership with #AZ for SCOPE #GP to predict EGFR mutation based on a H&E slide was a milestone for Lunit but it is only the beginning of the story! We can’t wait to share more updates on this partnership with AZ beyond EGFR.  • Looking forward to partnering with more biopharma companies and leading platforms in 2025 in addition to our current partnerships with Indica Labs and Roche Diagnostics. 🧑🏻🔬 Accelerating Research • We collaborated with #MDAnderson to predict responses to pembrolizumab in rare tumors with the power of AI • Also collaborated with #FoCR to demonstrate the level of agreement of HER2 biomarker assessment across independently developed computational pathology models. • More academic research collaborations are coming in 2025 to advance Oncology drug development. 🧾 Clinical Evidence  • We published 15 new #peer-reviewed journals and 24 abstracts in 2024.  • We look forward to sharing more high-impact publications in 2025 through more academic and biopharma collaborations. In 2025, we’ll continue pushing boundaries, driving innovation, and delivering AI-powered solutions that transform biomarker development. Stay tuned!

Lunit Oncology is proud of Sherry Kan, VP of Product Management and Marketing to be one of the 25 Women of Precision Medicine featured by DeciBio. Congratulations to Sherry and we're proud that you are part of Lunit Oncology.